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Abstract 
Eosinophilic enteritis is a rather rare condition that can manifest anywhere from 
esophagus to rectum. Its description in the literature is sparse, but associations have 
been made with collagen vascular disease, malignancy, food allergy, parasitic or viral 
infections, inflammatory bowel disease, and drug sensitivity. We present the case of a 
41-year-old male diagnosed with ulcerative colitis who underwent proctocolectomy 
with ileal pouch anal anastomosis and loop ileostomy formation utilizing Seprafilm, 
who later developed eosinophilic enteritis of the loop ileostomy site. This is the first 
report of eosinophilic enteritis and its possible link to the use of bioabsorbable adhesion 
barriers. 
 
Introduction 
Total proctocolectomy with ileal pouch anal anastomosis is considered a 
standard surgical approach for diffuse, medically refractory ulcerative colitis with 
rectal involvement. Loop ileostomy is commonly used to divert the fecal stream, and 
is employed as part of a two-staged procedure, with restoration of continuity after a 
minimum 6 week interval. Although the rate of anastomotic dehiscence remains 
unaffected by defunctioning stomas, diversion of the fecal stream after ileal pouch anal 
anastomosis can minimize the impact of pelvic sepsis from leak, thereby significantly 
reducing the morbidity and mortality of these procedures [1]. However, stomal 
complications can occur such as high output, fistula, dermatitis, infection, bleeding, 
retraction, prolapse, hernia, or obstruction [2]. Case Rep Gastroenterol 2011;5:422–427 
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Dense peristomal adhesions can lead to abdominal pain and bowel obstruction. 
Adhesions can also significantly impede mobilization of the stoma at the time of 
closure, thereby increasing the risk of enterotomy and unplanned bowel resection, 
resulting in prolonged operative times [3]. In order to reduce peristomal adhesion 
development, many surgeons have adopted the use of adhesion barriers for placement 
around defunctioning stomas at the time of formation [4]. Adhesion barriers vary in 
form and composition and are used in a multitude of intraabdominal and pelvic 
procedures for general surgery and gynecologic surgery applications. The most 
commonly used clinically successful types include solid barriers such as sodium 
hyaluronate/carboxymethylcellulose film (Seprafilm), oxidized regenerated cellulose 
(Interceed), and collagen film. Other types include fluid and gel barriers composed of 
collagen, carboxymethylcellulose, hyaluronate, polyethylene glycol, icodextrin, as well as 
fibrin glue, but ultimately these have shown less efficacy in preventing adhesion 
formation [5–7]. 
Few reports in the literature describe tissue inflammatory response from the use of 
adhesion barriers. Eosinophilic enteritis has not been previously described in association 
with adhesion barrier use, however it has been observed to occur in the settings of 
immune, infectious, and inflammatory conditions. Giant cell foreign body reaction has 
been documented with the use of hyaluronate/carboxymethylcellulose film, resulting in 
severe adhesion formation. With the broadening application of adhesion barriers, and 
with the growing popularity of hyaluronate/carboxymethylcellulose film across multiple 
surgical fields, it is of paramount importance to report potential adverse reactions. 
Case Report 
A 41-year-old Caucasian male presented for surgical evaluation for medically refractory 
ulcerative colitis. His diagnosis was established at an outside facility at the age of 36 after presenting 
with initial symptoms of diarrhea and grossly bloody stools with subsequent confirmation histologically. 
He was first started on Asacol 800 mg twice daily which had provided good symptomatic control for 
approximately 3 years. Unfortunately, the patient eventually developed recurrent symptoms of severe 
diarrhea with bowel movements in excess of 12 per day. Escalation therapy was attempted with 
Azathioprine 200 mg daily for 3 months but was stopped due to development of pancreatitis. An 8 week 
course of Remicade was given without symptomatic relief. 6-Mercaptopurine was attempted but was 
stopped after 2 days secondary to severe abdominal pain. His history included extraintestinal 
manifestation of scleritis of the right eye that resolved with topical prednisone. The patient was 
ultimately maintained on prednisone 30–50 mg daily for 1 year as well as Colazal 750 mg daily for 
6 months prior to his evaluation for surgery, however he continued to suffer from symptomatic 
ulcerative colitis.  
Preoperative CT enterography showed diffuse circumferential thickening of the entire colon, 
with no inflammatory changes of the small bowel. He underwent laparoscopic-assisted total 
proctocolectomy with ileal pouch anal anastomosis and loop ileostomy, with placement of 
Seprafilm on the loop ileostomy to facilitate future closure. Two months postoperatively he suffered 
bilateral pulmonary emboli necessitating warfarin therapy for a period of 6 months, delaying planned 
closure of his ileostomy. The patient noted daily episodes of minor bleeding from the ileostomy site 
without high output or local pain. He was found to have iron deficiency anemia and developed 
progressive eosinophilia without any obvious source. Stool cultures evaluating parasitic infection 
were negative. Adrenal insufficiency, which can manifest with eosinophilia due to the absence of 
glucocorticoid-induced eosinophil apoptosis, was also ruled out as an underlying cause. A review of 
biopsies from the colectomy performed 6 months earlier and of endoscopic biopsies of 2 years prior 
showed that they were without eosinophilia. At the time of ileostomy reversal 10 months later, 
dissection was extremely difficult due to a severe inflammatory reaction at the ileostomy site with a 
thickened membrane extending 10 cm along the bowel wall. The inflamed, indurated segment of bowel Case Rep Gastroenterol 2011;5:422–427 
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was resected and a hand-sewn anastomosis utilizing soft, pliable normal-appearing ileum was 
completed. There were no other gross intraoperative findings to suggest Crohn’s disease. Following 
resection of the inflamed area of ileum the eosinophilia resolved, going from a peak of 17.8% (normal  
0–6.6%) to 6.4%, with an absolute eosinophil count peak of 1.90 × 10
9/l (normal 0.0–0.4 × 10
9/l) abating 
to 0.47 × 10
9/l. 
Gross examination revealed dense focal adhesions of serosa with edema of the mucosa and bowel 
wall. There were no ulcers or masses. Hematoxylin and eosin staining was performed demonstrating 
severe diffuse intramural eosinophilic infiltrate (defined as ≥40/high power field) extending from the 
subserosal to submucosal layers (fig. 1). Serosal eosinophilic exudate was also present. There was 
nonspecific blunting of villi with no evidence of granulomas, active neutrophilic inflammation, or 
intraepithelial lymphocytes. Marked edema of the submucosa was also seen. 
Discussion 
Eosinophilic enteritis is defined as inflammation with characteristic eosinophilic 
infiltration of the bowel wall in which various layers can be affected, occurring anywhere 
along the gastrointestinal tract from esophagus to rectum [8, 9]. Serum eosinophilia is 
present in many cases. It is a relatively rare entity previously described in association 
with conditions such as collagen vascular disease, malignancy, food allergy, parasitic or 
viral infections, inflammatory bowel disease, and drug sensitivity [10–13]. Primary 
eosinophilic enteritis has also been described, where no precipitating factors can be 
identified leading to such inflammation [8]. It can present with various symptoms such as 
abdominal pain, protein-losing enteropathy, ulcers, ascites, obstruction, intussusception, 
perforation and can mimic inflammatory bowel disease [14–22]. Granulomatous 
formation has also been described along with eosinophilic infiltration [23]. Its association 
with bioresorbable membranes has not been previously described. 
Seprafilm is widely used in abdominal surgeries as a means to prevent intestinal 
adhesion formation [24]. It is composed of two chemically modified polysaccharides, 
hyaluronic acid and carboxycellulose, which are commonly found in pharmaceuticals, 
food and cosmetics. Upon hydration, Seprafilm transforms into a gel-like material over 
the 24–48 h after application. The gel remains in place during the critical 7 day period 
when new adhesions form. It is slowly resorbed and eventually excreted from the body 
over an estimated 28 day period. More recently, its application has been expanded to loop 
ileostomy formation in which the adhesion barrier is believed to facilitate dissection of the 
stoma at the time of closure [4, 25]. Complications reported that relate to bioresorbable 
membrane use include peritoneal inflammation, ascites, and increased leak formation 
when placed around an anastomosis. One notable report by David et al. described a severe 
inflammatory response to Seprafilm manifested by dense adhesion formation and giant 
cell foreign body reaction necessitating bowel resection [26]. Some however have found 
these claims to be controversial. One study evaluating the effect of Seprafilm on 
polymorphonuclear neutrophils, a key cellular component in the inflammatory response, 
found no significant influence on the overall function in polymorphonuclear neutrophils 
or cytokine production [27]. 
Our patient manifested with anemia and stomal bleed, and eosinophilia secondary to 
mucosal inflammation. He was also anticoagulated with warfarin, thus potentially 
exacerbating the stomal bleed and ultimately his anemia. One report by Chak et al. 
discussed a patient with chronic iron deficiency anemia and sarcoidosis being diagnosed 
with eosinophilic enteritis on evaluation by upper endoscopy. After treatment with Case Rep Gastroenterol 2011;5:422–427 
DOI: 10.1159/000329990 
Published online: 
August 18, 2011 
© 2011 S. Karger AG, Basel
ISSN 1662–0631 
www.karger.com/crg   
 
 
 
425
steroids, the patient’s anemia completely resolved [28]. Additional sources report 
favorable response of eosinophilic enteritis to steroid therapy [29]. Interestingly, our 
patient had been on prednisone therapy for ulcerative colitis and this was weaned in the 
subsequent months following colectomy. Shortly after complete discontinuation of 
prednisone, he was noted to develop the aforementioned symptoms of eosinophilia, 
anemia, and stomal bleed. The inflammatory reaction was localized to the segment of 
bowel forming the ileostomy and after resection of the involved portion of bowel, the 
patient’s anemia and eosinophilia completely resolved. 
Conclusion 
Although Seprafilm has generally shown utility in preventing adhesion formation 
after laparotomy and aids stomal closure, the sequela of eosinophilic enteritis with dense 
adhesion formation provides further evidence of possible paradoxical reactions to 
bioresorbable membrane use. Further investigation and reporting is required to fully 
substantiate this potentially serious but treatable condition. 
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Fig. 1. Eosinophilic enteritis: microscopy with hematoxylin and eosin stain. Eosinophilic infiltrate 
involves the intestinal wall from the subserosa to the submucosa (line and arrows) but spares the 
mucosa (20×). The inset shows a higher power view of the infiltrate of eosinophils (200×). 
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